SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

American Express Co. engages in the provision of card-issuing, merchant-acquiring, and card network businesses. Its products and services include credit cards, business credit cards, corporate programs, gift cards, savings accounts and CDs, and the American Express App. It operates through the following segments: the United States Consumer Services (USCS), Commercial Services (CS), International Card Services (ICS), Global Merchant and Network Services (GMNS), and Corporate and Other. The USCS segment includes proprietary consumer cards and provides services to United States consumers. The CS segment offers corporate and small business cards and provides services to United States businesses. The ICS segment provides consumers, small businesses, and corporate cards outside the United States. The GMNS segment is involved in operating a global payments network that processes and settles card transactions, acquires merchants, and provides multi-channel marketing programs and capabilities, services and data analytics. The Corporate and Other segment covers corporate functions and certain other businesses and operations. It also operates through the following geographical segments: United States, EMEA, APAC, LACC, and Other. The EMEA segment represents Europe, the Middle East, and Africa. The APAC segment refers to Asia Pacific, Australia, and New Zealand. The LACC segment focuses on Latin America, Canada, and the Caribbean. The Other segment includes net costs which are not directly allocated to specific geographic regions. The company was founded by Henry Wells, William G. Fargo, and John Warren Butterfield on March 28, 1850 and is headquartered in New York, NY.

American Express Co.

American Express shares are under pressure after earnings beat expectations and the company raised its full-year EPS outlook, as traders focus on planned workforce cuts and restructuring costs; a slight revenue shortfall and rising expenses also drew scrutiny. Some investors argue the strong results and guidance outweigh those concerns.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Okta is rallying with cybersecurity peers as AI-related vulnerabilities and autonomous agents sharpen demand for identity and AI security, with traders pointing to the companys role in securing AI identities. Bulls see the theme supporting growth, while skeptics argue the sharp run-up is difficult to justify given Oktas modest growth and high valuation.

Blacksky Technology, Inc. is a space-based intelligence company, which engages in the business of delivering real-time imagery, analytics, and high-frequency monitoring of most critical and strategic locations, economic assets, and events. The firm is also involved in providing geospatial intelligence, imagery and related data analytic products and services, and mission systems that include the development, integration, and operation of satellite and ground systems to government and commercial customers. The company was founded in 2014 and is headquartered in Herndon, VA.

BlackSky Technology Inc - Ordinary Shares - Class A

BlackSkys expanded seven-figure Gen-3 contract with an international defense partner is drawing attention, but traders are debating why the shares remain weak despite contract wins. Some see the deals as evidence of execution, while others are focused on the steep decline and upcoming Q3 results.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

A sharp rally and unusually heavy bullish call activity ahead of earnings are driving attention, with bulls pointing to Snaps Specs AR glasses and a proposal to sell an outside stake in the unit as potential catalysts. Others question whether the enthusiasm can last, citing ad-market concerns and the risk that options-driven momentum fades.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. The firm offers various products for application security, performance and reliability, network services, Zero Trust, developer platform, media delivery, insights, domain registration, and consumer services. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare shares are drawing attention as cybersecurity stocks rally around the PHP2Shell vulnerabilities, with traders viewing Cloudflares web application firewall as a potential beneficiary because it can block exploit traffic. The move has prompted bullish momentum trading, while some traders warn against chasing the sharp gain or focus on the stocks valuation.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddits upcoming earnings report is the main focus, with traders watching for evidence that ad growth can offset concerns about user trends and the lack of new AI data-licensing deals. Sentiment is split between bulls citing improving ad monetization and business fundamentals, and frustrated bears pointing to the stocks weak, choppy performance and questioning whether earnings can revive it.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRSP is drawing attention ahead of the CTX310 Phase 1b presentation at the AHA meeting, with traders focused on whether the in-vivo gene-editing data could validate the cardiovascular program. Reactions are mixed: some are positioning around the readout, while others are concerned about the stocks persistent range-bound trading and the CFO transition, which some view as unsettling despite reports of an orderly handoff.

Palo Alto Networks, is a cybersecurity company that provides cybersecurity platforms and services to enterprises, organizations, service providers, and government entities. Its offerings include network and AI security, cloud security, security operations, and identity security solutions. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is rising with cybersecurity peers as AI-related vulnerabilities and escalating threat reports renew expectations for security spending; an Evercore channel survey cited by traders also points to firming enterprise budgets. The reaction is broadly bullish, though some traders question whether the sectors sharp rally is justified by already-stretched valuations.

Fervo Energy Co. operates as a energy company. It builds and operates power facilities in extracting geothermal energy. The company was founded by Jack Norbeck and Timothy Latimer in 2017 and is headquartered in Berkeley, CA.

Fervo Energy Co. - Ordinary Shares - Class A

Fervo Energy Co

FRVO is drawing attention amid a steep selloff and debate over a Morpheus short report questioning Fervos geothermal performance, including water recovery and project economics; investors also cite transmission constraints and potential IPO-related selling. Bears see serious execution risks, while bulls dismiss the report as biased and point to Cape Stations first power and Google contracts as evidence of progress.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubriks strong quarterly results and raised outlook are driving renewed attention, but shares initially sold off as investors focused on slower cloud net-new ARR growth and cautious second-half guidance. The community is split between treating the pullback as a buying opportunity and arguing that elevated expectations and concerns about management guidance could keep pressure on the stock.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology...

Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

Summit Therapeutics Inc. (NASDAQ: SMMT) and Lunit Inc. (KRX: 328130) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunits AI-powered pathology platform, for tumor microenvironment analysis in support of Summits immuno-oncology development programs with ivonescimab. The...

Summit Expands Ivonescimab Development Into Biliary Tract Cancer

SMMT is advancing ivonescimab into BTC, launching a phase II/III study to compare its survival benefits with established immunotherapy regimens.

Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that ivonescimab data will be featured in numerous presentations at the European Society for Medical Oncology 2026 Congress (ESMO 2026), taking place October 23-27, 2026, in Madrid, Spain. Across 10 presentations at ESMO 2026, ivonescimab data...

Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?

Summit is expanding ivonescimab beyond lung cancer into colorectal, bladder, kidney and other cancers, backed by promising early data and collaboration deals.

Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial...

Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in a registration-enabling Phase II/III study in biliary...

Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the initiation and opening of clinical trial sites of a multiregional Phase II study of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in previously untreated advanced clear cell renal cell...

SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos

Summit is teaming up with AstraZeneca and Daiichi to test ivonescimab with Datroway across breast and lung cancers, broadening its potential.

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZenecas (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the development of ivonescimab, a novel, potential first-in-class investigational...

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Novartis inked a deal with China’s Abogen on Friday, marking the week’s largest headline number, at up to $7.8 billion.</li><li>Sanofi and Regeneron, partners since 2007 on the eczema drug Dupixent, said on Thursday they will co-develop four new long-acting antibodies aimed at the same kind of inflammation.</li><li>Novo paid $300 million upfront for rights to HRS-1596 outside mainland China, Hong Kong, Macao, and Taiwan, in a deal worth up to $2.6 billion including milestones.&nbsp;</li></ul><p>Drugmakers spent the week buying time in the categories they cannot afford to lose: experimental autoimmune drugs, next-generation obesity pills and cancer combinations.</p><p>Novartis and Novo Nordisk went to China for early RNA and oral metabolic assets. Sanofi paid to extend the inflammation franchise behind Dupixent. AstraZeneca and Merck, meanwhile, invested in cancer mechanisms.</p><h2 class="st-heading-2">Novartis Bets On An RNA Immune Drug</h2><p>Novartis inked a deal with China’s Abogen on Friday, marking the week’s largest headline number, at up to $7.8 billion. Under the deal, Novartis gets exclusive worldwide rights to ABO2203, an RNA drug designed to make the body produce a protein that clears disease-causing immune cells. The target diseases are autoimmune conditions such as lupus and rheumatoid arthritis.</p><p>Abogen also gave Novartis options on other programs from its RNA platform. The deal includes an upfront payment of $575 million; the remaining $7.2 billion depends on development, approval, and sales milestones, and on those options being taken. Royalties would follow if a drug is sold. The deal still needs customary clearances.</p><h2 class="st-heading-2">Sanofi Pays To Extend Dupixent Franchise</h2><p>Sanofi and Regeneron, partners since 2007 on the eczema drug Dupixent, said on Thursday they will co-develop four new long-acting antibodies aimed at the same kind of inflammation. Sanofi’s $1 billion upfront is the largest cash payment of the week, against a $7.8 billion ceiling at Novartis that is mostly milestones.</p><p>The companies will split development costs and profits on the new drugs equally. Dupixent’s existing split does not change. One candidate, REGN20423, is already in early testing for atopic dermatitis. The other three are expected to enter studies in 2027. The pact also settles litigation between the two companies.</p><h2 class="st-heading-2">Novo Licenses A Once-Weekly Obesity Pill</h2><p>Novo Nordisk’s Tuesday agreement with Hengrui was narrower than the Novartis pact.</p><p>HRS-1596 is ready for early human testing as a once-weekly oral treatment that hits two appetite and blood-sugar pathways, GLP-1 and GIP. Novo paid $300 million upfront for rights outside mainland China, Hong Kong, Macao, and Taiwan, in a deal worth up to $2.6 billion including milestones, plus royalties on sales in that territory. Hengrui has Chinese clearance to start early-stage studies in weight management and type 2 diabetes. The license still needs U.S. antitrust clearance and is expected to close in the fourth quarter.</p><h2 class="st-heading-2">AstraZeneca Invests $2B To Test Summit's Cancer Drug</h2><p>AstraZeneca’s $2 billion investment in Summit Therapeutics, announced late Monday, is equity, not a license. The point is access to ivonescimab, a dual-target antibody that blocks PD-1, an immune brake, and VEGF, a signal tumors use to build blood vessels. The companies will test it with AstraZeneca’s experimental cancer drug sonesitatug vedotin in certain gastrointestinal cancers. Each side keeps the rights to its own molecule.</p><h2 class="st-heading-2">Merck Takes A Lab-Stage Cancer Pill</h2><p>Merck’s Monday deal is the earliest of the week. SPR2015, from SciBrunch, is a lab-stage pill aimed at KRAS G12D, a common cancer mutation with few approved drugs aimed at it. Merck takes worldwide rights for $400 million upfront, in a deal worth up to $2.13 billion, and will book that payment as a third-quarter charge of about $0.13 a share. SciBrunch can earn the rest if the drug hits development and commercial goals.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around <a class="mention" data-mention="$NVS" data-symbol-id="NVS" href="https://stocktwits.com/symbol/NVS" target="_blank">NVS</a> and MRK was 'bearish' at the time of writing, while sentiment around AZN, SNY, and NVO was 'neutral.' Retail sentiment around SMMT and REGN, however, was 'bullish' or 'extremely bullish.'&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/novo-holds-its-2026-outlook-as-fda-review-of-its-blood-disorder-drug-runs-long/cZDjsS6RBKY">Novo Nordisk Holds Its 2026 Outlook As FDA Review Of Its Blood Disorder Drug Runs Long</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

 Assorted pharmaceutical drugs balancing on each other, conceptional idea .

Biotech companies this week spent on experimental therapies, including autoimmune drugs, next-generation obesity pills and cancer combinations.

AstraZeneca PLC

Merck & Co Inc

Novartis AG

Regeneron Pharmaceuticals, Inc.

Sanofi-Aventis

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$15.47
Prev Close	$15.55
Open	$15.46
Dividend Yield	0.00%
50-Day Moving Average	$15.79
Beta	1.61
Avg. Volume	7.56M
PE Ratio	-13.82

52-Week High	$29.23
52-Week Low	$12.07
Market Capitalization	$12.37B
EPS (Annual)	-$1.44
Price to Book	19.48
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

SMMT Fundamentals